V. Catros-quemener, F. Bouet, and N. Genetet, Immunité anti-tumorale et thérapies cellulaires du cancer, Med Sci (Paris), vol.19, pp.43-53, 2003.

S. A. Rosenberg, J. C. Yang, and R. M. Sherry, Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy, Clin Cancer Res, vol.17, pp.4550-4557, 2011.

V. Catros, O. Toutirais, and F. Bouet, Lymphocytes T?? en cancérologie : des lymphocytes tueurs non conventionnels, Med Sci, vol.26, pp.185-91, 2010.

M. Ruella and M. Kalos, Adoptive immunotherapy for cancer, Immunol Rev, vol.257, pp.14-38, 2014.

M. Castellarin, K. Watanabe, and C. H. June, Driving cars to the clinic for solid tumors, Gene Ther, vol.25, pp.165-75, 2018.

M. Sadelain, I. Riviere, and S. Riddell, Therapeutic T cell engineering, Nature, vol.545, pp.423-454, 2017.

U. Kohl, S. Arsenieva, A. Holzinger, and H. Abken, CAR T cells in trials : Recent achievements and challenges that remain in the production of modified T cells for clinical applications, Hum Gene Ther, vol.29, pp.559-68, 2018.

G. Gross, T. Waks, and Z. Eshhar, Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proc Natl Acad Sci, vol.86, pp.10024-10032, 1989.

P. Hwu, G. E. Shafer, and J. Treisman, Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain, J Exp Med, vol.178, pp.361-367, 1993.

L. J. Cooper, M. S. Topp, and L. M. Serrano, T-cell clones can be rendered specific for CD19 : toward the selective augmentation of the graft-versus-B-lineage leukemia effect, Blood, vol.101, pp.1637-1681, 2003.

M. A. Pule, B. Savoldo, and G. D. Myers, Virus-specific T cells engineered to coexpress tumor-specific receptors : persistence and antitumor activity in individuals with neuroblastoma, Nat Med, vol.14, pp.1264-70, 2008.

J. N. Kochenderfer, W. H. Wilson, and J. E. Janik, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, vol.116, pp.4099-102, 2010.

D. L. Porter, B. L. Levine, and M. Kalos, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, vol.365, pp.725-758, 2011.

R. J. Brentjens, M. L. Davila, and I. Riviere, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med, vol.5, pp.177-215, 2013.

M. L. Davila, I. Riviere, and X. Wang, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, vol.6, pp.224-249, 2014.

D. L. Porter, W. T. Hwang, and N. V. Frey, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, vol.7, pp.303-139, 2015.

B. Jordan, Immunothérapie « CAR-T » : une autorisation qui fait date, Med Sci, vol.33, pp.1003-1009, 2017.

M. A. Perales, P. Kebriaei, L. S. Kean, and M. Sadelain, Biol Blood Marrow Transplant, vol.24, pp.27-31, 2018.

L. A. Johnson and C. H. June, Driving gene-engineered T cell immunotherapy of cancer, Cell Res, vol.27, pp.38-58, 2017.

Y. Liu, C. Zhao, and L. Gao, Considerations for clinical review of cellular therapy products : perspectives of the china food and drug administration center for drug evaluation, Hum Gene Ther, vol.29, pp.121-128, 2018.

W. A. Lim and C. H. June, The principles of engineering immune cells to treat cancer, Cell, vol.168, pp.724-764, 2017.

D. M. O'rourke, M. P. Nasrallah, and A. Desai, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med, vol.9, 2017.

A. D. Posey, R. D. Schwab, and A. C. Boesteanu, Engineered CAR T cells targeting the cancer-associated tn-glycoform of the membrane mucin MUC1 control adenocarcinoma, Immunity, vol.44, pp.1444-54, 2016.

K. Newick, S. O'brien, E. Moon, and S. M. Albelda, CAR T cell therapy for solid tumors, Annu Rev Med, vol.68, pp.139-52, 2017.

M. Hudecek, D. Sommermeyer, and P. L. Kosasih, The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity, Cancer Immunol Res, vol.3, pp.125-160, 2015.

O. U. Kawalekar, R. S. Oc, and J. A. Fraietta, Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells, Immunity, vol.44, p.712, 2016.

A. Ribas and J. D. Wolchok, Cancer immunotherapy using checkpoint blockade, Science, vol.359, pp.1350-1355, 2018.

V. Catros, B. Dessarthe, A. Thedrez, and O. Toutirais, Les récepteurs de nectines/nectines-like DNAM-1 et CRTAM. Immuno-surveillance ou échappement tumoral ?, Med Sci, vol.30, pp.537-580, 2014.

C. Granier, A. Gey, and C. Dariane, Tim-3. Biomarqueur et cible thérapeutique en cancérologie, Med Sci, vol.34, pp.231-238, 2018.

A. C. Anderson, N. Joller, and V. K. Kuchroo, Lag-3, Tim-3, and TIGIT : Co-inhibitory receptors with specialized functions in immune regulation, Immunity, vol.44, pp.989-1004, 2016.

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, pp.252-64, 2012.

D. S. Chen and I. Mellman, Elements of cancer immunity and the cancer-immune set point, Nature, vol.541, pp.321-351, 2017.